Exécution de notre outil de synthèse sur un nouvel article
Vérifiez l’article ci-dessous, puis lancez sa synthèse.
Graft Localized Immunomodulation with Rapamycin-Eluting PLGA Microparticles Promotes Murine Islet Allograft Survival and Induces Operational Tolerance
Jordan Wong (University of Alberta), Purushothaman Kuppan (University of Alberta), Nerea Cuesta‐Gomez (University of Alberta), Jiaxin Lin (University of Alberta), Joy Paramor (University of Alberta), Chelsea Castro (University of Alberta), Kateryna Polishevska (University of Alberta), A K Bose (University of Alberta), Colin C. Anderson (University of Alberta), Gregory S. Korbutt (University of Alberta), Andrew R. Pepper (University of Alberta)
Résumé : Islet transplantation effectively restores physiologic glycemic regulation in a subset of individuals living with type 1 diabetes; however, lifelong systemic immunosuppression remains a major barrier to broader patient inclusion. Herein, we explored the use of a localized drug delivery system to preserve islet allograft function, circumventing systemic immunosuppression. Rapamycin (Rapa) was effectively encapsulated within poly(lactic-co-glycolic acid) microparticles (MP), which facilitated sustained and localized drug release to the islet grafts, modulating the immune environment and significantly prolonging allograft survival (p<0.05). Long-term outcomes were further enhanced when Rapa-MP was combined with low-dose, acute systemic CTLA-4-Ig therapy. Combination therapy induced operational tolerance, with 100% allograft survival for more than 200 days. Our localized MP drug delivery system, whether used as monotherapy or as part of combination therapy, has the potential to favourably modulate the immune environment, protect islet grafts, and serve as a safe adjuvant to clinical islet transplantation.